Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
EXACT Therapeutics AS ( (DE:56F) ) has provided an update.
EXACT Therapeutics AS announced that several major shareholders and primary insiders, including Investinor Direkte AS, entities associated with board member Leiv Askvig, chair Anders Wold, and Canica AS, have committed to exercise all of their warrants, following GE Medical Holdings AB’s earlier decision to exercise its full warrant allocation. Together, these exercises represent 75% of the warrants issued in the December 2024 private placement and are expected to generate gross proceeds of NOK 46 million, strengthening the company’s capital base ahead of an extraordinary general meeting to issue new shares and providing additional financial runway for its clinical development activities.
More about EXACT Therapeutics AS
EXACT Therapeutics AS is a clinical-stage precision medicine company listed on Euronext Growth Oslo that leverages ultrasound technology to activate its proprietary drug candidate PS101, aiming to enhance the efficacy of oncology treatments. The platform’s mechanism allows PS101 to be combined with a broad range of cancer therapies and potentially applied to other indications, including brain diseases, positioning the company within the emerging field of ultrasound-mediated drug delivery.
Average Trading Volume: 41,242
Current Market Cap: NOK120.2M
Find detailed analytics on 56F stock on TipRanks’ Stock Analysis page.